Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Shortly before COVID-19 patients’ conditions advance from moderate to severe, their levels of type I interferon (IFN) are present in the bloodstream drop.
“Joining the board will allow me to help guide and influence the development of a product from bench to bedside,” Franchimont told BioSpace. “I look forward to contributing to ongoing discussions on translation from bench science to the clinic, and ultimately to making real differences in the lives of patients.”
The new research hub will be called the London Discovery Research Centre and is expected to open by 2025.
Together the two companies will scour comprehensive medical and molecular data sets of thousands of chronic kidney disease patients to identify and then develop possible drugs.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
The 11-person team at Codagenix may be tiny, but it has big plans for the company’s new COVID-19 vaccine.
In the midst of an international pandemic, three high-profile public health officials are leaving government service.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
DBV Technologies aims to fill the peanut allergy treatment gap, especially for highly allergic children, with their low dose epicutaneous immunotherapy (EPIT) patch Viaskin™ Peanut.
Niclosamide is an oral anthelminthic drug. It was first approved by the U.S. Food and Drug Administration (FDA) in 1982 and is included in the World Health Organization (WHO)’s list of essential medicines.